Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.21.2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Oct. 31, 2020
Segment Reporting Information [Line Items]          
Net Income/(Loss) $ (4,387,610) $ (2,576,787) $ (9,056,876) $ (7,851,352)  
Total operating costs and expenses 4,388,236 2,435,969 9,571,149 7,735,975  
Less non-cash share-based compensation (3,187,326) (1,041,799) (5,224,697) (3,173,219)  
Operating costs and expenses excluding non-cash share-based compensation 1,200,910 1,394,170 4,346,452 4,562,756  
Total assets 37,062,391   37,062,391   $ 9,452,964
CAR-T Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net Income/(Loss) (1,618,860) (417,502) (4,025,354) (1,542,865)  
Operating costs and expenses excluding non-cash share-based compensation 411,313 189,589 1,903,707 759,752  
Total assets 12,709,167   12,709,167   2,988,124
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net Income/(Loss) (1,464,323) (178,738) (3,033,026) (544,605)  
Operating costs and expenses excluding non-cash share-based compensation 348,535 72,968 1,185,060 238,297  
Total assets 10,706,026   10,706,026   946,923
Anti-Viral Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net Income/(Loss) (1,262,260) (281,098) (2,052,821) (590,602)  
Operating costs and expenses excluding non-cash share-based compensation 418,285 155,224 826,716 376,242  
Total assets 12,849,445   12,849,445   2,464,361
Cancer Diagnostics [Member]          
Segment Reporting Information [Line Items]          
Net Income/(Loss) (38,198) (1,693,304) (60,569) (5,162,977)  
Operating costs and expenses excluding non-cash share-based compensation 20,645 971,698 37,368 3,180,511  
Total assets 682,943   682,943   2,869,529
Patent Licensing [Member]          
Segment Reporting Information [Line Items]          
Net Income/(Loss) (3,969) (6,145) 114,894 (10,303)  
Operating costs and expenses excluding non-cash share-based compensation 2,132 $ 4,691 393,601 $ 7,954  
Total assets $ 114,810   $ 114,810   $ 184,027